

Attorney Docket No.
02973.00031Serial No. 
TBAINFORMATION DISCLOSURE CITATION
Sheet 1 of 2

Applicant(s): Thanos HALAZONETIS et al.

Filing Date: Herewith

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
SJM	94/08241	4/1994	WO				
SJM	95/17213	6/1995	WO				
SJM	0 518 650	12/1992	EP				
SJM	94/12202	1994	WO				
SJM	94/10306	5/1994	WO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

SJM	Coller et al., "Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M-induced Cleavage and Inactivation," <i>J. Biol. Chem.</i> , 268(28):20741-20743 (1993)
SJM	Couder et al., "Synthesis and Biological Activities of $\psi(\text{CH}_2\text{NH})$ Pseudopeptide Analogues of the C-terminal Hexapeptide of Neurotensin," <i>Internat. J. Peptide & Protein Res.</i> , 41(2):181-184 (1993)
SJM	DalPozzo et al., "H-Gly-His $\psi(\text{NHCO})$ Lys-OH, Partially Modified <i>Retro-Inverso</i> Analogue of the Growth Factor Glycyl-L-histidyl-l-lysine with Enhanced enzymatic Stability," <i>Int. J. Peptide Protein Res.</i> , 41:561-566 (1993)
SJM	Hupp et al., "Regulation of the Cryptic Sequence-Specific DNA-Binding Function of p53 by Protein Kinases," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LIX, pp. 195-205 (1994)
SJM	Hupp et al., "Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53," <i>Cell</i> , 83:237-245 (1995)
SJM	Shaw et al., "Regulation of Specific DNA Binding by p53: Evidence for a Role of o-Glycosylation and Charged Residues at the Carboxy-terminus," <i>Oncogene</i> , 12:921-930 (1996)
SJM	Takenaka et al., "Regulation of the Sequence-Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases," <i>J. Biol. Chem.</i> , 270(10):5405-5411 (1995)
SJM	Tanigaki et al., "The Peptide Binding Specificity of HLA-B27 Subtypes," <i>Immunogenetics</i> , 40:192-198 (1994)
SJM	Powell et al., "Peptide Stability in Drug Development. II. Effect of Single Amino acid Substitution and Glycosylation on Peptide Reactivity in Human Serum," <i>Pharmaceutical Research</i> , 10(9):1268-1273 (1993)
SJM	Brady et al., "Reflections on a Peptide," <i>Nature</i> , 368:692-693 (1994)
SJM	Hupp et al., Allosteric Activation of Latent p53 Tetramers," <i>Current Biology</i> , 4(10):865-875 (1994)
SJM	Wade-Evans et al., "Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53," <i>EMBO J.</i> , 4:699-706 (1985)
SJM	Finlay et al., "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093 (1989)
SJM	Soussi et al., "Structural Aspects of the p53 Protein in Relation to Gene Evolution," <i>Oncogene</i> , 5:945-952 (1990)
SJM	Hupp et al., "Regulation of the Specific DNA Binding Function of p53," <i>Cell</i> , 71:857-886 (1992)
SJM	Hruby, "Conformational and Topographical Consideration in the Design of Biologically Active Peptides," <i>Biopolymers</i> , 33:1073-1082 (1993)

PRO

1040 U.S. 829912
04/11/01

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 02973.00031	Serial No. TBA
INFORMATION DISCLOSURE CITATION Sheet 1 of 2		Applicant(s): Thanos HALAZONETIS et al.	
		Filing Date: Herewith	Group:
SJM	Hupp et al., "Activation of the Cryptic DNA Binding Function of Mutant Forms of p53," <i>Nucleic Acids Res.</i> , 21:3167-3174 (1993)		
SJM	Fujiwara et al., "A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis," <i>Cancer Res.</i> , 53:4129-4133 (1993)		
SJM	Halazonetis et al., "Wild-Type p53 Adopts a 'Mutant'-like Conformation when Bound to DNA," <i>EMBO J.</i> , 12:1021-1028 (1993)		
SJM	Halazonetis et al., "Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Finding Domain and Restore DNA Binding to Select p53 Mutants," <i>EMBO J.</i> , 12:5057-5064 (1993)		
SJM	Bugg et al., "Drugs by Design," <i>Sci. Am.</i> , 269:92-98 (1993)		
SJM	Friend, "p53: A Glimpse at the Puppet Behind the Shadow Play," <i>Science</i> , 265:334-335 (1994)		
SJM	Cho et al., "Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations," <i>Science</i> , 265:346-355 (1994)		
SJM	Clore et al., "High Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR," <i>Science</i> , 265:386-391 (1994)		
SJM	Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis," <i>Science</i> , 265:391-394 (1994)		
SJM	Cox et al., "Xenopus p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced upon DNA Damage in Somatic Cells," <i>Oncogene</i> , 9:2951-2959 (1994)		
SJM	Jameson et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis," <i>Nature</i> , 368:744-746 (1994)		
SJM	Moore, "Designing Peptide Mimetics," <i>Trends Pharmacol. Sci.</i> , 15:124-129 (1994)		
SJM	Dean, "Recent Advances in Drug Design Methods" Where Will They Lead?" <i>BioEssays</i> , 16:683-687 (1994)		
SJM	Naoko Arai et al., "Immunologically Distinct p53 Molecules Generated by Alternative Splicing," <i>Molecular and Cellular Biology</i> , Vol 6, No. 9, September 1986, p. 3232-3239		
SJM	Stryer. Biochemistry Second Edition, p. 13-17		
EXAMINER <i>Aluffi</i>		DATE CONSIDERED 6/3/03	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
**Copies of references not provided at the time of this submission.			